Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $8.30 Average PT from Analysts

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have earned a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $8.30.

CGTX has been the subject of a number of research analyst reports. HC Wainwright upped their price objective on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $1.00 to $1.50 in a report on Thursday, December 19th. Chardan Capital reissued a “buy” rating and set a $11.00 price objective on shares of Cognition Therapeutics in a report on Thursday, December 19th. Finally, Brookline Capital Management raised shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th.

Cognition Therapeutics Stock Performance

Shares of NASDAQ CGTX opened at $0.61 on Wednesday. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95. The stock has a market cap of $25.39 million, a PE ratio of -0.63 and a beta of 0.96. The business has a fifty day moving average of $0.67 and a two-hundred day moving average of $0.58.

Hedge Funds Weigh In On Cognition Therapeutics

Several institutional investors have recently modified their holdings of CGTX. Virtu Financial LLC increased its position in shares of Cognition Therapeutics by 40.1% during the fourth quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock worth $56,000 after acquiring an additional 22,949 shares in the last quarter. Sigma Planning Corp boosted its stake in Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares during the period. Geode Capital Management LLC increased its holdings in Cognition Therapeutics by 8.9% during the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock worth $247,000 after purchasing an additional 28,705 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Cognition Therapeutics in the 4th quarter valued at about $26,000. Finally, Two Sigma Investments LP lifted its holdings in shares of Cognition Therapeutics by 372.2% in the fourth quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after purchasing an additional 42,321 shares in the last quarter. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.